StockPreacher.com announces an investment report featuring GenVec Inc. (Nasdaq:GNVC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/GNVC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher
GenVec Inc. (GNVC) is a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer. Using GNVC's core adenovector technology, TNFerade stimulates the production of tumor necrosis factor alpha (TNFa), a known anti-tumor protein, in cells of the tumor. In addition to its therapeutic product development programs, GNVC is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus and Herpes Simplex Virus Type 2 (HSV-2).
Message Board Search for GNVC: http://www.boardcentral.com/boards/GNVC
In the report, the analyst notes:
"GNVC last week announced financial results for the fourth quarter and year ended December 31, 2009. For the fourth quarter ended December 31, 2009, GNVC reported a net loss of $4.3 million, or $0.04 per share, compared with a net loss of $6.4 million, or $0.07 per share, for the comparable prior year period. The Company reported revenues of $3.4 million in the fourth quarter of 2009 compared to $3.3 million for the same period in 2008.
"GNVC recently announced the publication of new preclinical research revealing mechanisms by which TNFerade™ suppresses cancer metastases through activation of the immune system."